Abstract
Allergen immunotherapy with subcutaneous injection (SCIT) of the relevant allergen is the classic causal treatment method for IgE-mediated allergic respiratory disease and has already been successfully used for over 100 years. This publication is based on a selective literature search in PubMed and MEDLINE. Recent publications in German-language journals that are not available in literature databases were also analyzed. This literature search included original and review articles both in German and in English. Primary, secondary and tertiary prevention characteristics have been demonstrated for SCIT; however, these require further evaluation. In combination with biologic agents, the safety, and in some cases the efficacy, of SCIT can be increased. Adjuvants seem to offer enormous development potential for SCIT. Aluminum salts, microcrystalline tyrosine (MCT), and monophosphoryl lipid A (MPL) are already used in commercial SCIT preparations. At the same time, other adjuvants are being researched, e.g., liposomes, microspheres, CpG motifs (C: nucleotide cytosine, p: phosphate, G: nucleotide guanine), or virus-like particles (VLPs). The therapeutic extracts themselves are also undergoing further development, for instance as recombinant allergens, hypoallergenic variants such as site-directed mutants (SDM), conformational variants, allergen fragmentation, allergen oligomers, deletion mutants, and hybrid allergens/mosaic antigens. SCIT preparations are among the most innovative treatment options in the immunotherapy of allergic diseases. Due to the numerous immunological approaches, they will make treatment safer and more effective in the future with reduced effort.
Highlights
Allergen-specific immunotherapy (AIT) with subcutaneous administration of allergen extracts has been the standard procedure for the treatment of inhalant and insect venom allergies for over 100 years.In addition to its efficacy and safety in the treatment of existing symptoms [1, 2], a number of primary, secondary, and tertiary preventive properties have been demonstrated for subcutaneous injection (SCIT) [3, 4]
Controlled but open studies on individual preparations have shown that SCIT has preventive effects in addition to its efficacy on symptoms
Szépfalusi et al treated 31 children exhibiting monosensitization to mites or grasses but no previous symptoms of clinical relevance, with oral immunotherapy using the relevant allergen over 2 years, or observed them in the no-treatment placebo group over the same period
Summary
Allergen-specific immunotherapy (AIT) with subcutaneous administration of allergen extracts (subcutaneous immunotherapy; SCIT) has been the standard procedure for the treatment of inhalant and insect venom allergies for over 100 years.In addition to its efficacy and safety in the treatment of existing symptoms [1, 2], a number of primary, secondary, and tertiary preventive properties have been demonstrated for SCIT [3, 4]. Combining biologic agents with SCIT increases the safety of the treatment. Compared with other treatment options, SCIT is cost-effective and can save disease-related costs in the long term [5, 6]. Allergens or allergoids in commercial extracts in Germany are usually physically adsorbed to a carrier, e.g., aluminum hydroxide (Al(OH)3) or microcrystalline tyrosine (MCT) [4]. These provide the properties of a deposit, and act as adjuvants. Allergen immunotherapy with subcutaneous injection (SCIT) of the relevant allergen is the classic causal treatment method for IgE-mediated allergic respiratory disease and has already been successfully used for over 100 years
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
